H.R. 7391 · 119th Congress · Health

Community Health Center Drug Pricing Protection Act

In committee306 words Introduced Feb 5, 2026 · Latest action Feb 5, 2026

How far it has goneStage 2 of 6
  1. IntroducedFeb 5, 2026 Done
  2. CommitteeReferred to Energy and Commerce Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

Full text

No CRS summary yet · 306 words

H.R. 7391 · Introduced in House · Feb 5, 2026

SECTION 1. SHORT TITLE.

This Act may be cited as the Community Health Center Drug Pricing Protection Act .

SEC. 2. ENSURING UPFRONT 340B DISCOUNTED PRICING FOR FEDERALLY-QUALIFIED HEALTH CENTERS.

(a) In general. Section 340B(a) of the Public Health Service Act ( 42 U.S.C. 256b(a) ) is amended by adding at the end the following new paragraph: (11) Upfront discounted pricing for Federally-qualified health centers The Secretary may not enter into an agreement with a manufacturer of covered outpatient drugs under paragraph (1) under which the amount required to be paid to the manufacturer for covered outpatient drugs by a covered entity described in paragraph (4)(A) exceeds, at the point of purchase of such drug, the applicable ceiling price for such drug (as described in paragraph (1)). .

(b) Rule of construction. Nothing in this section, or the amendment made by this section, shall be construed to permit under paragraph (1) of section 340B(a) of the Public Health Service Act ( 42 U.S.C. 256b(a) ) any arrangement under which a covered entity described in paragraph (4)(A) of such section pays to the manufacturer of a covered outpatient drug an amount in excess of the applicable ceiling price for such drug (as described in such paragraph (1)) at the time of purchase, with later reconciliation by rebate, reimbursement, or other payment.

(c) Effective dates. (1) In general The amendments made by this section shall take effect on the date of the enactment of this section and shall apply to drugs purchased on or after the date of the enactment of this section. (2) Application to existing agreements Beginning on the date of the enactment of this section, the amendments made by this section shall be taken into account in determining whether an agreement with a manufacturer of covered outpatient drugs meets the requirements of section 340B(a) of the Public Health Service Act ( 42 U.S.C. 256b(a) ).

Shown here because the text is under 500 words. Open on Congress.gov

Who lobbies on it

6 organizations, more than 94% of House bills · 14 filings · Q1 2026–Q3 2026

These 6 organizations’ PACs gave $115K to 19 of the 59 members sponsoring or cosponsoring H.R. 7391 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the House → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Amgen Inc 3 of 3 quarters
    “…HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and…”

    $8.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. Bristol-Myers Squibb Company 3 of 3 quarters
    “Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization…”

    $7.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  3. Advocates for Community Health 3 of 3 quarters
    “…the Community Health Center Drug Pricing Protection Act (HR 7391). Comments and legislative efforts to block 340B Rebate Model Pilot Program efforts and manufacturers efforts to compel claims data Issues and legislation related to the primary care workforce, including the Developing the Community Health Workforce Act…”

    $235K lobbying spend in 2026 to date, all issuesQ3 2026 filing

3 more organizations, every filingPROUpgrade

Organizations that named H.R. 7391 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Feb 5, 2026Referred to the House Committee on Energy and Commerce.
  2. Feb 5, 2026Introduced in House

What members said about it

  • Statement · Press release · Nov 11, 2026 · Bergman R-MI

    Bergman, Ruiz Introduce Bipartisan Bill to Preserve Critical Drug Discounts for Safety Net Providers

    On October 29, Reps. Jack Bergman and Dr. Raul Ruiz, M.D., introduced the Safety Net Provider Drug Pricing Protection Act (H.R. 10919), bipartisan legislation to preserve critical prescription drug discounts for rural hospitals, community…

    “Safety net providers are the backbone of healthcare in our communities. These lifelines serving our most vulnerable patients depend on the 340B program to keep their doors open and cannot afford the devastating upfront costs of the new pilot Rebate model. The Safety Net Provider Drug Pricing Protection Act is a…”